Literature DB >> 25574612

IL-17-targeting biologics aim to become standard of care in psoriasis.

Mark Ratner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25574612     DOI： 10.1038/nbt0115-3

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  First PDE4 inhibitor for psoriasis hits the market but impact is uncertain.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2014-06       Impact factor: 54.908
  1 in total
  11 in total

1.  First eczema biologic debuts but price could restrict use.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2017-05-09       Impact factor: 54.908

2.  New anti-IL-23 drugs raise hopes for psoriasis plaque clearance.

Authors:  Elie Dolgin
Journal:  Nat Biotechnol       Date:  2016-12-07       Impact factor: 54.908

3.  Hyperinsulinemia enhances interleukin-17-induced inflammation to promote prostate cancer development in obese mice through inhibiting glycogen synthase kinase 3-mediated phosphorylation and degradation of interleukin-17 receptor.

Authors:  Sen Liu; Qiuyang Zhang; Chong Chen; Dongxia Ge; Yine Qu; Rongyi Chen; Yi-Ming Fan; Nan Li; Wendell W Tang; Wensheng Zhang; Kun Zhang; Alun R Wang; Brian G Rowan; Steven M Hill; Oliver Sartor; Asim B Abdel-Mageed; Leann Myers; Qishan Lin; Zongbing You
Journal:  Oncotarget       Date:  2016-03-22

Review 4.  A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis.

Authors:  Molly Campa; Bobbak Mansouri; Richard Warren; Alan Menter
Journal:  Dermatol Ther (Heidelb)       Date:  2015-12-29

5.  Absorption of Codonopsis pilosula Saponins by Coexisting Polysaccharides Alleviates Gut Microbial Dysbiosis with Dextran Sulfate Sodium-Induced Colitis in Model Mice.

Authors:  Yaping Jing; Anping Li; Zhirong Liu; Pingrong Yang; Junshu Wei; Xinjun Chen; Tang Zhao; Yanrui Bai; Lajia Zha; Chunjiang Zhang
Journal:  Biomed Res Int       Date:  2018-08-19       Impact factor: 3.411

Review 6.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

Review 7.  Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome.

Authors:  Israr Khan; Naeem Ullah; Lajia Zha; Yanrui Bai; Ashiq Khan; Tang Zhao; Tuanjie Che; Chunjiang Zhang
Journal:  Pathogens       Date:  2019-08-13

8.  Cutaneous Immune Cell-Microbiota Interactions Are Controlled by Epidermal JunB/AP-1.

Authors:  Özge Uluçkan; Maria Jiménez; Ben Roediger; Jakob Schnabl; Lucía T Díez-Córdova; Kevin Troulé; Wolfgang Weninger; Erwin F Wagner
Journal:  Cell Rep       Date:  2019-10-22       Impact factor: 9.423

9.  Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis Registry.

Authors:  Jessica A Walsh; Kristina Callis Duffin; Abby S Van Voorhees; Soumya D Chakravarty; Timothy Fitzgerald; Amanda Teeple; Katelyn Rowland; Jonathan Uy; Robert R McLean; Wendi Malley; Angel Cronin; Joseph F Merola
Journal:  Dermatol Ther (Heidelb)       Date:  2021-11-25

10.  Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Authors:  Jack L Arbiser; Ron Nowak; Kellie Michaels; Yuliya Skabytska; Tilo Biedermann; Monica J Lewis; Michael Y Bonner; Shikha Rao; Linda C Gilbert; Nabiha Yusuf; Isabella Karlsson; Yi Fritz; Nicole L Ward
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.